Literature DB >> 35344407

Empagliflozin Reverses Late Na+ Current Enhancement and Cardiomyocyte Proarrhythmia in a Translational Murine Model of Heart Failure With Preserved Ejection Fraction.

Bence Hegyi1, Juliana Mira Hernandez1,2, Erin Y Shen1, Nima R Habibi1, Julie Bossuyt1, Donald M Bers1.   

Abstract

Entities:  

Keywords:  arrhythmia, cardiac; empagliflozin; heart failure, diastolic; sodium channels; sodium-glucose transporter 2 inhibitors

Mesh：

Substances：

Year:  2022        PMID： 35344407      PMCID： PMC8969782          DOI： 10.1161/CIRCULATIONAHA.121.057237

Source DB:  PubMed          Journal:  Circulation        ISSN： 0009-7322            Impact factor:   29.690


× No keyword cloud information.
  5 in total

1.  Empagliflozin in Heart Failure with a Preserved Ejection Fraction.

Authors:  Stefan D Anker; Javed Butler; Gerasimos Filippatos; João P Ferreira; Edimar Bocchi; Michael Böhm; Hans-Peter Brunner-La Rocca; Dong-Ju Choi; Vijay Chopra; Eduardo Chuquiure-Valenzuela; Nadia Giannetti; Juan Esteban Gomez-Mesa; Stefan Janssens; James L Januzzi; Jose R Gonzalez-Juanatey; Bela Merkely; Stephen J Nicholls; Sergio V Perrone; Ileana L Piña; Piotr Ponikowski; Michele Senni; David Sim; Jindrich Spinar; Iain Squire; Stefano Taddei; Hiroyuki Tsutsui; Subodh Verma; Dragos Vinereanu; Jian Zhang; Peter Carson; Carolyn Su Ping Lam; Nikolaus Marx; Cordula Zeller; Naveed Sattar; Waheed Jamal; Sven Schnaidt; Janet M Schnee; Martina Brueckmann; Stuart J Pocock; Faiez Zannad; Milton Packer
Journal:  N Engl J Med       Date:  2021-08-27       Impact factor: 176.079

2.  Nitrosative stress drives heart failure with preserved ejection fraction.

Authors:  Gabriele G Schiattarella; Francisco Altamirano; Dan Tong; Kristin M French; Elisa Villalobos; Soo Young Kim; Xiang Luo; Nan Jiang; Herman I May; Zhao V Wang; Theodore M Hill; Pradeep P A Mammen; Jian Huang; Dong I Lee; Virginia S Hahn; Kavita Sharma; David A Kass; Sergio Lavandero; Thomas G Gillette; Joseph A Hill
Journal:  Nature       Date:  2019-04-10       Impact factor: 49.962

Review 3.  SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control.

Authors:  Martin R Cowie; Miles Fisher
Journal:  Nat Rev Cardiol       Date:  2020-07-14       Impact factor: 32.419

4.  Cardiac Late Sodium Channel Current Is a Molecular Target for the Sodium/Glucose Cotransporter 2 Inhibitor Empagliflozin.

Authors:  Koenraad Philippaert; Subha Kalyaanamoorthy; Mohammad Fatehi; Wentong Long; Shubham Soni; Nikole J Byrne; Amy Barr; Jyoti Singh; Jordan Wong; Taylor Palechuk; Chloe Schneider; Ahmed M Darwesh; Zaid H Maayah; John M Seubert; Khaled Barakat; Jason R B Dyck; Peter E Light
Journal:  Circulation       Date:  2021-04-09       Impact factor: 29.690

5.  Empagliflozin reduces Ca/calmodulin-dependent kinase II activity in isolated ventricular cardiomyocytes.

Authors:  Julian Mustroph; Olivia Wagemann; Charlotte M Lücht; Maximilian Trum; Karin P Hammer; Can Martin Sag; Simon Lebek; Daniel Tarnowski; Jörg Reinders; Filippo Perbellini; Cesare Terracciano; Christof Schmid; Simon Schopka; Michael Hilker; York Zausig; Steffen Pabel; Samuel T Sossalla; Frank Schweda; Lars S Maier; Stefan Wagner
Journal:  ESC Heart Fail       Date:  2018-08
  5 in total
  2 in total

Review 1.  Antiarrhythmic effects and mechanisms of sodium-glucose cotransporter 2 inhibitors: A mini review.

Authors:  Jinchun Wu; Yanmin Liu; Xiaojuan Wei; Xiaofei Zhang; Yi Ye; Wei Li; Xiaoling Su
Journal:  Front Cardiovasc Med       Date:  2022-08-08

2.  SGLT2 Inhibitor Empagliflozin Modulates Ion Channels in Adult Zebrafish Heart.

Authors:  Alexey V Karpushev; Valeria B Mikhailova; Ekaterina S Klimenko; Alexander N Kulikov; Dmitry Yu Ivkin; Elena Kaschina; Sergey V Okovityi
Journal:  Int J Mol Sci       Date:  2022-08-23       Impact factor: 6.208
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.